The current European guidelines for the management of hypertension 1 state that lifestyle measures should be instituted in all hypertensive patients; however, the long-term compliance with their implementation is notoriously low. All our patients receive lifestyle counseling according to good practice guidelines. However the OLAS study 2 was focused in the comparison of two pharmacological treatments and not on the relative merits of lifestyle and medication.
As Thomopoulos et al. 3 point out, no reduction in body mass index or waist circumference was achieved in our study. It cannot be concluded, though, that the overall cardiovascular risk of our patients was not reduced, as large reductions in blood pressure and albuminuria were attained in both treatment arms. The patients receiving olmesartan/amlodipine showed better metabolic and anti-inflammatory effects than their olmesartán/ hydrocholothiazide counterparts. It is still unknown whether these effects may reduce further their cardiovascular risk, but in the ACCOMPLISH trial, 4 with a similar treatment strategy, a highly significant reduction in cardiovascular mortality and morbidity was observed with the benazepril/amlodipine combination compared with the benazepril/hydrochlorothiazide combination. This difference could only be attributed to the effects of medication and not to lifestyle changes.
The 'hypertension paradox' described by Chobanian 5 refers to the fact that in spite of improved pharmacological therapy, the burden of uncontrolled hypertension keeps growing. In the OLAS study, close to 80% of the patients were successfully controlled in both treatment arms, therefore it can hardly be considered as an example of hypertension paradox.
Thomopoulos et al. 3 also refer to some possible confounders, such as the circadian blood pressure rhythm, the sleep apnea syndrome, the 24-h sodium excretions and the timing of the blood pressure measurements. In a subset of the patients of the ACCOMPLISH trial, 6 ambulatory monitoring of blood pressure was performed and no differences could be found between the treatment arms, supporting the interpretation that the observed difference in cardiovascular outcomes was not caused by differences in blood pressure, but by intrinsic properties of the studied combination therapies. In hypertensive patients with the sleep apnea syndrome, treatment with olmesartán has been shown to reduce blood pressure and insulin resistance without changing the body mass index or the severity of the sleep apnea syndrome. 7 In the OLAS study, a parallel group, prospective, randomized, open label, blinded end point design (PROBE) was used. The number of patients in both arms (60 for each arm) was adequate for the studied end points, and they were very well matched at baseline for all the measured variables. A successful randomization ensured that all the observed differences in outcomes could only be attributed to the respective drug treatments, as it made highly unlikely that they could be attributed to the lack of lifestyle changes or to the mentioned (or any other conceivable) confounding factors.
Remarks by Thomopoulos et al. 3 remind us that lifestyle counseling is all too often the Cinderella of hypertension management, 8 and that weight loss should be more aggressively pursued in high-risk patients with metabolic syndrome.
